Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures
Mucopolysaccharidosis VI (MPS VI) is an inheritable, clinically heterogeneous lysosomal storage disorder that develops due to a deficiency in the arylsulfatase B (ASB) enzyme. This deficiency impairs the stepwise degradation of glycosaminoglycans (GAGs) resulting in the accumulation of partia...
Saved in:
| Main Author: | Paul Harmatz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hacettepe University Institute of Child Health
2010-10-01
|
| Series: | The Turkish Journal of Pediatrics |
| Online Access: | https://turkjpediatr.org/article/view/5045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early Diagnosis and Results of Enzyme Replacement Therapy in the Patient with Mucopolysaccharidosis Type VI: Clinical Case
by: Dmitry V. Ivanov, et al.
Published: (2021-12-01) -
Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020-02-01) -
EFFICACY AND SAFETY OF ENZYME REPLACEMENT THERAPY IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS TYPE I, II, AND VI: A SINGLE-CENTER COHORT STUDY
by: Liliia A. Osipova, et al.
Published: (2018-04-01) -
Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2021-12-01) -
Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II
by: Alex J. Shamoun, et al.
Published: (2025-01-01)